In May 2019, a milestone resolution on transparency in pharmaceutical markets was adopted by the 72nd World Health Assembly. One year later, this event will reflect on efforts to implement it at national level, challenges that have arisen and ongoing debates. How does transparency shape innovation and access to medicines and diagnostics? What is the relevance of transparency to the ongoing COVID-19 crisis? Panelists will address these questions from government, civil society, academic and industry perspectives, looking at both national and global levels. This event is co-organised by the Global Health Centre and Observatoire de la transparence dans les politiques du médicament (OTMeds).
- Lenias Hwenda, Co-Chair, WHA 72.8 Transparency Resolution Negotiations; Founder and CEO, Medicines for Africa
- Luca Li Bassi, Co-Chair, WHA 72.8 Transparency Resolution Negotiations; Former AIFA General Director
- Caroline Fiat, Member of French Parliament, Co-Author of Amendments on Transparency in Medicines Policies
- Mustaqeem de Gama, Counsellor, South African Permanent Mission to the WTO
- Paul Fehlner, President and CEO, reVision Therapeutics, Inc.
- Pauline Londeix, Co-Founder, OTMeds; Access to Medicines Advocate and Researcher
- Suerie Moon, Co-Director, Global Health Centre; Visiting Lecturer, The Graduate Institute